Literature DB >> 7908201

Focal transgene expression associated with papilloma development in v-Ha-ras-transgenic TG.AC mice.

L A Hansen1, R Tennant.   

Abstract

The homozygous transgenic mouse line TG.AC contains a v-Ha-ras transgene and rapidly develops epidermal papillomas in response to either wounding or treatment with tumor promoters such as 12-O-tetradecanoylphorbol-13-acetate (TPA). The transgenic v-Ha-ras protein product was detected in all papillomas removed from TPA-treated TG.AC mice but not in vehicle- or TPA-treated TG.AC skin without tumors. In situ hybridization demonstrated that focal expression of the transgene was limited to regions of papilloma development and further localized the expression of the transgene message to the epidermal component of the papillomas, with the strongest signal in the basal epidermoid cells. Cellular proliferation, as indicated by immunohistochemical staining for proliferating-cell nuclear antigen (PCNA), was similarly localized primarily to basal epidermoid cells and, to a lesser extent, stratum spinosum cells in all papillomas analyzed. Cells that stained positively for PCNA were much more common in the papillomas than in the surrounding, normal-appearing skin. The focal nature of papilloma development was also evidenced by protein kinase C activity and hyperplasia after TPA treatment. As early as 18 d after the start of TPA treatment, focal hyperplasias associated with the follicular epidermis were observed in TG.AC but not nontransgenic FVB/N skin; these hyperplasias were assumed to be the precursors of the epidermal papillomas. To explain the development of transgene-expressing tumors from apparently transgene-negative, normal-appearing skin, we hypothesize that the papillomas arise from the clonal expansion of focal areas of epidermal cells that overexpress the transgene. We also propose that the TG.AC line is an excellent model for studying very early events in papillomagenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908201     DOI: 10.1002/mc.2940090306

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  8 in total

1.  Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo.

Authors:  A I Robles; M L Rodriguez-Puebla; A B Glick; C Trempus; L Hansen; P Sicinski; R W Tennant; R A Weinberg; S H Yuspa; C J Conti
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

Review 2.  Transgenic mice and squamous multistage skin carcinogenesis.

Authors:  K Brown; A Balmain
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

3.  Follicular origin of epidermal papillomas in v-Ha-ras transgenic TG.AC mouse skin.

Authors:  L A Hansen; R W Tennant
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

4.  Association of v-Ha-ras transgene expression with development of erythroleukemia in Tg.AC transgenic mice.

Authors:  C S Trempus; S Ward; G Farris; D Malarkey; R S Faircloth; R E Cannon; J F Mahler
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

5.  Regulation of epidermal differentiation by a Distal-less homeodomain gene.

Authors:  M I Morasso; N G Markova; T D Sargent
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

6.  Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays.

Authors:  R W Tennant
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

7.  Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.

Authors:  C T Siegel; K Schreiber; S C Meredith; G B Beck-Engeser; D W Lancki; C A Lazarski; Y X Fu; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

8.  Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models.

Authors:  R W Tennant; J E French; J W Spalding
Journal:  Environ Health Perspect       Date:  1995-10       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.